title: [Efficacy of combined immunocorrection in the treatment of chronic viral hepatitis C].
abstract: OBJECTIVE
  To assess efficacy of combined immunocorrection in the treatment of patients with chronic viral hepatitis C (CVHC).
  
  
  METHODS
  Routine clinicobiochemical tests, examination of immunological homeostasis (cellular immunity, the level of circulating immune complexes - CIC and their molecular composition, macrophagal phagocyting system - MPS) were made in two groups of CVHC patients: the study group (n=68) and control group (n=66). The control patients received standard treatment, the study group received also cyclopheron in combination with reamberin. Cyclopheron was given per os in a single daily dose 600 mg 2 days, then 3 times a week in a dose 150 mg for 48 weeks. Reamberin infusions in a single daily dose 400 ml were made for 5 - 7 days.
  
  
  RESULTS
  CVHC in exacerbation phase is characterized by the presence of secondary immunodeficiency running with T-lymphopenia, low count of peripheral blood lymphocytes with CD4+ phenotype and low immunoregulatory index CD4/CD8, depression of functional activity of T-cells as evidenced by lymphocyte blast transformation test with phytohemagglutinin, inhibition of phagocyting activity of monocytes and inhibition of dermal macrophages. This shows subnormal functional activity of MPS. CVHC runs with accumulation of CIC in blood serum primarily due to increased content of most pathogenic mid- and low-molecular .ifactions of immune complexes. Addition ofcyclopheron and reamberin in combined treatment of CVHC patients promotes normalization of immunological homeostasis which clinically occurs in parallel with achievement of persistent and long-term CVHC remission.
  
  
  CONCLUSIONS
  The results of the above investigation support pathogenetic validity and prospects of cyclopheron and reamberin inclusion into combined treatment of CVHC.
authors.forename: V M
authors.initials: VM
authors.lastname: Frolov
authors.forename: Ia A
authors.initials: IaA
authors.lastname: Sotskaia
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000936:Antigen-Antibody Complex / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D018655:Lymphocyte Count; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D010587:Phagocytosis / Q000187:drug effects; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000166:Acridines; D000936:Antigen-Antibody Complex; D000998:Antiviral Agents; D007369:Interferon Inducers; D016898:Interferon-alpha; C549374:Reamberin; D013386:Succinates; D012254:Ribavirin; D008536:Meglumine; C026430:10-carboxymethyl-9-acridanone